What SEC filings does MAIA Biotechnology, Inc. submit to the SEC?

MAIA Biotechnology, Inc. (MAIA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about MAIA?

A Form 4 for MAIA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from MAIA Biotechnology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for MAIA?

The 10-K is MAIA Biotechnology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all MAIA SEC filings directly on EDGAR?

You can view all historical MAIA Biotechnology, Inc. filings on the SEC EDGAR company page for MAIA. Each filing card on this page links directly to the original SEC document.

How often does MAIA Biotechnology, Inc. file with the SEC?

MAIA Biotechnology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling MAIA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

MAIA SEC Filing News — MAIA Biotechnology, Inc.

Latest SEC filings for MAIA Biotechnology, Inc. (MAIA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Sector: Healthcare Industry: Biotechnology Market Cap: $66.4M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for MAIA currently lean bullish. Of the 12 displayed SEC filing records, 5 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 11 insider transactions (Form 4) in this period.

MAIA Filing Activity Snapshot 2026-08-24 — 2026-10-06

Insider Transactions (Form 4)

5 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$184.1K

Guerrero Ramiro (Director) · 2026-09-01

133,790 shares · Form 4

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for MAIA Biotechnology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 compensation award and 5 open-market purchase. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×5: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

Theagene Jean-Manasse (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	32,012	—	—

Filing: Form 4 (Insider Transaction) Insider: Theagene Jean-Manasse (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

Smith Stan (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	38,871	—	—

Filing: Form 4 (Insider Transaction) Insider: Smith Stan (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

Luput Cristian (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	33,536	—	—

Filing: Form 4 (Insider Transaction) Insider: Luput Cristian (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

Louie Ngar Yee (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	39,634	—	—

Filing: Form 4 (Insider Transaction) Insider: Louie Ngar Yee (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

Guerrero Ramiro (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	32,012	—	—

Filing: Form 4 (Insider Transaction) Insider: Guerrero Ramiro (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

MAIA insider Form 4 filed for equity award, exercise, or tax withholding

CHAOUKI STEVEN M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	32,774	—	—

Filing: Form 4 (Insider Transaction) Insider: CHAOUKI STEVEN M (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-15

MAIA insider Vitoc Vlad (Director, Chief Executive Officer, 10% Owner) bought 73,000 shares (~$100.0K)

Vitoc Vlad, listed as Director, Chief Executive Officer, 10% Owner at MAIA Biotechnology, Inc., reported an open-market purchase of 73,000 MAIA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	73,000	$1.37	$100.0K

Filing: Form 4 (Insider Transaction) Insider: Vitoc Vlad (Director, Chief Executive Officer, 10% Owner) Shares: 73,000 Est. Value: $100.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-14

MAIA insider Guerrero Ramiro (Director) bought 37,595 shares (~$49.5K)

Guerrero Ramiro, listed as Director at MAIA Biotechnology, Inc., reported an open-market purchase of 37,595 MAIA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	37,595	$1.32	$49.5K

Filing: Form 4 (Insider Transaction) Insider: Guerrero Ramiro (Director) Shares: 37,595 Est. Value: $49.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-01

MAIA insider Guerrero Ramiro (Director) bought 133,790 shares (~$184.1K)

Guerrero Ramiro, listed as Director at MAIA Biotechnology, Inc., reported an open-market purchase of 133,790 MAIA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	8,931	$1.39	$12.4K
`P`	Open-market purchase	78,239	$1.39	$108.8K
`P`	Open-market purchase	46,620	$1.35	$62.9K

Filing: Form 4 (Insider Transaction) Insider: Guerrero Ramiro (Director) Shares: 133,790 Est. Value: $184.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-26

MAIA insider Guerrero Ramiro (Director) bought 1,794 shares (~$2.4K)

Guerrero Ramiro, listed as Director at MAIA Biotechnology, Inc., reported an open-market purchase of 1,794 MAIA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,794	$1.33	$2.4K

Filing: Form 4 (Insider Transaction) Insider: Guerrero Ramiro (Director) Shares: 1,794 Est. Value: $2.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-24

MAIA insider Guerrero Ramiro (Director) bought 11,899 shares (~$16.3K)

Guerrero Ramiro, listed as Director at MAIA Biotechnology, Inc., reported an open-market purchase of 11,899 MAIA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	11,899	$1.37	$16.3K

Filing: Form 4 (Insider Transaction) Insider: Guerrero Ramiro (Director) Shares: 11,899 Est. Value: $16.3K

View on SEC EDGAR → Open Filing Document →

Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for MAIA Biotechnology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-06

MAIA filed 8-K — material company event

MAIA Biotechnology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

How we classify MAIA Biotechnology, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MAIA. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MAIA SEC Filings

More Tools for MAIA

MAIA Full Stock Analysis MAIA Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MAIA analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MAIA stock analysis page.

MAIA Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer